A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Trial details
- Registry ID
- NCT06564324
- Phase
- Phase 3
The FDA approved Crizotinib (XALKORI) on 26 Aug 2011.
Drug identity checked against registry records
Also recorded as XALKORI
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsNCT06564324 | NUVB | Phase 3 | Recruiting | 2029-01Estimated |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 | IDEAYA Biosciences | Phase 2, Phase 3 | Active not recruiting | 2027-01-15Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-08-26Day | Crizotinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA202570", "applicant_as_listed_by_fda": "PF PRISM CV", "brand_names": ["XALKORI"], "active_ingredients": ["CRIZOTINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20110826", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |